Plos One:绝经激素疗法或能保护女性心脏

2018-03-24 佚名 嘉音

3月8日,在线发表于《Plos One》杂志上的一项研究显示,接受绝经激素疗法(MHT)的女性,心脏会得到更好的保护,从而使其具有较低的心衰风险。

3月8日,在线发表于《Plos One》杂志上的一项研究显示,接受绝经激素疗法(MHT)的女性,心脏会得到更好的保护,从而使其具有较低的心衰风险。

虽然目前MHT(又称作激素替代疗法)对绝经后妇女心血管健康的治疗效果仍充满争议。但大量的观察性数据显示,MHT对于心脏是具有保护作用的,所以也就使得MHT被医生作为常规处方用于冠心病的一级预防和二级预防。然而,来自于妇女健康倡议研究(WHI)和雌激素/孕激素替代治疗研究(HERS)的数据则提示,MHT并不具有心血管保护作用。因此,本项研究的目的在明确MHT是否对心血管存在保护效应。

该研究采用的研究数据来自于英国生物样本库(UKBiobank),这个数据库是一个包含超过500000人健康问卷调查数据、生物样本数据和身体测量数据的大型数据库。同时,英国这个数据库还包括心血管磁共振(MRI)影像数据,这个影像数据是分析心脏结构和功能的金标准。

该研究通过MRI共检查了1604名未患心血管疾病的绝经后女性的左心室(LV)与左心房(LA)的结构和功能,这其中有32%的人曾经接受至少3年的MHT治疗。

研究结果显示,MHT的使用不仅与心脏结构和功能的不利改变没有关系,实际上还能使LV与LA腔体积明显缩小,从而带来较好的心血管结局,这其中就包括较低的死亡率和心衰风险。同时,研究者还观察到这些绝经后女性LV重量的提升,意味着她们存在较高的心血管疾病发病率和死亡率。但重要的是,研究者发现这两个群体之间(接受MHT治疗和未接受MHT治疗)的LV重量没有显著的差异。

本研究作者,来自玛丽皇后伦敦大学的Mihir Sanghvi博士认为:“这是第一个研究MHT与心脏的结构和功能变化的相关性研究,这个问题非常重要,因为在英国有230万的女性正在接受MHT治疗,而这一治疗方法的效果尚存在争议。通过使用英国生物样本库的数据,我们发现MHT的使用与心脏结构和功能的不利改变并无关系,相反,该治疗方法还具有一定的心脏保护作用。”

此外,研究者声称:“虽然,之前的一些研究揭示了MHT对心脏的积极和消极效果,使得MHT对心脏健康的效果仍旧不清楚。但本研究为MHT对心脏健康的积极效果添加了更进一步证据,可能会使正在接受此项治疗的女性放心。然而,女性不应该特意通过MHT来改善心脏健康,因为本研究并没有考虑到MHT对心血管健康影响的方方面面。举个例子来说,有一些证据表明,MHT有可能增加血栓形成的风险,意味着我们仍需要进一步的研究来明确MHT对心血管健康的效果。”

“对于绝大多数处于更年期的女性来说,特别是60岁以下的女性,进行MHT的好处大于任何潜在的风险。然而,每个个体的情况不同,还是需要咨询医生MHT是否适合自己。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790128, encodeId=feab1e901285b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Nov 19 04:26:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300390, encodeId=08b8300390fb, content=不错耶学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 28 06:46:37 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257148, encodeId=5b0f125e148f6, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531163, encodeId=48e11531163c6, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299755, encodeId=8119299e55dd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Mar 26 07:15:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790128, encodeId=feab1e901285b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Nov 19 04:26:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300390, encodeId=08b8300390fb, content=不错耶学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 28 06:46:37 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257148, encodeId=5b0f125e148f6, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531163, encodeId=48e11531163c6, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299755, encodeId=8119299e55dd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Mar 26 07:15:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-28 owlhealth

    不错耶学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1790128, encodeId=feab1e901285b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Nov 19 04:26:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300390, encodeId=08b8300390fb, content=不错耶学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 28 06:46:37 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257148, encodeId=5b0f125e148f6, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531163, encodeId=48e11531163c6, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299755, encodeId=8119299e55dd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Mar 26 07:15:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790128, encodeId=feab1e901285b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Nov 19 04:26:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300390, encodeId=08b8300390fb, content=不错耶学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 28 06:46:37 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257148, encodeId=5b0f125e148f6, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531163, encodeId=48e11531163c6, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299755, encodeId=8119299e55dd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Mar 26 07:15:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1790128, encodeId=feab1e901285b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Nov 19 04:26:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300390, encodeId=08b8300390fb, content=不错耶学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Mar 28 06:46:37 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257148, encodeId=5b0f125e148f6, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531163, encodeId=48e11531163c6, content=<a href='/topic/show?id=ad8f668407d' target=_blank style='color:#2F92EE;'>#激素疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66840, encryptionId=ad8f668407d, topicName=激素疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=822512217606, createdName=lisa442, createdTime=Mon Mar 26 08:26:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299755, encodeId=8119299e55dd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Mar 26 07:15:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-26 owlhealth

    学习了

    0

相关资讯

Brit J Cancer:绝经后妇女饮酒与雌激素代谢产物之间的相关性分析!

由此可见,绝经后妇女饮酒量与雌激素水平之间存在相关性,但与雌激素代谢物的浓度无关,提示可能受到MHT和饮酒类型的影响。

J Thromb Haemost:绝经后妇女血管舒缩症状与静脉血栓形成的风险!

由此可见,尽管在发表的研究中血管舒缩症状与其他心血管事件的风险有关,但该研究的发现并不表明血管舒缩症状是VT风险的一个标志。

JCEM:绝经后抗骨质疏松症治疗会引起循环微小RNA改变!

由此可见,循环中miRs受特立帕肽和狄诺塞麦治疗的影响具有差异。采用特立帕肽治疗会影响到与Runx-2(miR-33)及DKK-1(miR-133)基因表达相关的miRs相对表达。

Menopause:绝经后激素治疗与脑血管意外死亡风险

一项最新观察性研究显示,停止绝经后激素治疗(HT)的60岁以下女性1年内心源性及卒中所致死亡风险会增加,但在60岁以上女性中则未见上述风险增加。

Osteoporos Int:绝经后骨质疏松女性:双磷酸盐类“药物假期”增加骨折风险?

2017年12月,发表在《Osteoporos Int》的一项由法国科学家进行的回顾性分析, 考察了绝经后骨质疏松女性中,双磷酸盐(BPs)类药物假期治疗对临床骨折风险的影响。

JCEM:绝经后妇女高雄激素与动脉粥样硬化和心血管疾病风险分析!

由此可见,绝经后较高的雄激素水平与CVD风险增加无关。多囊卵巢综合征患者的心血管健康可能比预期的要好。